In her letter Dr. Goodman suggests that the CTG/CAG expansion which we detected in the Danish schizophrenia kindred [Sirugo et al., 1997] could affect the expression of transthyretin (TTR), which would in turn alter the delivery of retinoids to the fetal brain and result in a schizophrenia phenotype
Reply to Professor Niermeijer and Dr. Los
โ Scribed by ten Kate, Leo P.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 859 B
- Volume
- 73
- Category
- Article
- ISSN
- 0148-7299
- DOI
- 10.1002/(sici)1096-8628(19971231)73:4<490::aid-ajmg22>3.0.co;2-l
No coin nor oath required. For personal study only.
โฆ Synopsis
It hurts to be accused of paternalism. Nevertheless, since my intention was to stir up some discussion on the subject of disclosure of prenatally established carrier status, I welcome the reaction of Prof. Niermeijer and Dr. Los.
They argue that disclosure ''will enable parents to deal with the genetic problem in their family in a responsible manner.'' Unfortunately they do not tell us their opinion on testing young children for carriership when parents ask for it. I suppose they do not object to such testing as, again, it ''will enable parents to deal with the genetic problem in their family in a responsible manner.'' If this assumption is correct, Prof. Niermeijer and Dr. Los at least support my point that, perhaps, one should not think differently about testing young children and disclosing carrier status established prenatally. However, if their view on testing young children is different, they would help us by explaining where we have to draw the line. Is it birth? Is it whether we are testing for carriership or future disease? Is it whether results are obtained while testing for something else? Is it the height of the reproductive risk?
I hope we will be able to advance the discussion on the basis of well-founded opinions and experience.
๐ SIMILAR VOLUMES